FDA Approves Phase II Kidney Cancer Therapy Study
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy, TLX250.
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product Illuccix®
Telix In-Licences Novel Tumour Microenvironment PET Tracer
Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de Louvain.
Japanese Prostate Cancer Imaging Study Completes Enrolment
Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa University.
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Telix announces collaboration with Kettering Health on PSMA-targeting theranostics
Michael Didocha Joins Telix as Chief Financial Officer, Americas
Telix is delighted to announce the appointment of Michael Didocha as Chief Financial Officer for the Americas region.
Samantha McSherry Joins Telix as Director of Commercial Operations ANZ
Telix is delighted to announce that Samantha McSherry has joined Telix as Director of Commercial Operations for Australia and New Zealand.
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS)
Half Year Shareholder Update
Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
AUDIO LINK NOT ATTACHED – Telix Half-Year Results 2021 and Company Update Conference Call
Telix announces Half-Year Results 2021 and provides shareholder update